Investigating the role of CDHR5 in preventing colorectal cancer
CDHR5 tumor suppressor function in the intestine
This study is looking at how a protein called CDHR5 helps keep our intestines healthy and may prevent colorectal cancer, and it’s exploring whether a medication called 5-ASA can boost this protein's protective effects to help develop better ways to prevent this type of cancer.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Toledo NIH-funded |
| Lab location | 1 site (Toledo, United States) |
| Project ID | NIH-10299388 on NIH RePORTER |
What this research studies
This research focuses on understanding how the CDHR5 protein functions as a tumor suppressor in the intestine, particularly in relation to colorectal cancer (CRC). The study explores how CDHR5 interacts with other proteins to maintain the structure of intestinal cells and prevent tumor formation. By examining the effects of the drug 5-ASA on CDHR5 expression, the research aims to uncover potential new therapies for CRC prevention. Patients may benefit from insights that could lead to improved chemopreventive strategies against colorectal cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for colorectal cancer, including those with a family history or other predisposing factors.
Not a fit: Patients who have already been diagnosed with advanced colorectal cancer may not benefit directly from this research.
Why it matters
Potential benefit: If successful, this research could lead to new preventive treatments for colorectal cancer that enhance the function of CDHR5.
How similar studies have performed: Previous research has shown promising results in understanding the role of adhesion molecules in cancer prevention, suggesting that this approach may yield valuable insights.
Where this research is happening
Toledo, United States
- University of Toledo — Toledo, United States (Active)
Researchers
- Principal investigator: Crawley, William Scott — University of Toledo
- Study coordinator: Crawley, William Scott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.